MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Abbott Laboratories

Suletud

SektorTervishoid

123.73 2.37

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

123.53

Max

124.48

Põhinäitajad

By Trading Economics

Sissetulek

-7.9B

1.3B

Müük

-616M

10B

P/E

Sektori keskmine

17.147

39.857

Aktsiakasum

1.09

Dividenditootlus

1.74

Kasumimarginaal

12.792

Töötajad

114,000

EBITDA

-324M

2.7B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+17.79% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.74%

2.42%

Järgmine tulemuste avaldamine

15. okt 2025

Järgmine dividendimakse kuupäev

15. aug 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. okt 2025

Turustatistika

By TradingEconomics

Turukapital

1.9B

230B

Eelmine avamishind

121.36

Eelmine sulgemishind

123.73

Uudiste sentiment

By Acuity

41%

59%

138 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Abbott Laboratories Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuli 2025, 12:10 UTC

Tulu

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16. apr 2025, 16:21 UTC

Tulu

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16. apr 2025, 12:14 UTC

Tulu

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17. juuli 2025, 13:14 UTC

Tulu

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17. juuli 2025, 12:16 UTC

Tulu

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17. juuli 2025, 11:32 UTC

Tulu

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17. juuli 2025, 11:32 UTC

Tulu

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17. juuli 2025, 11:31 UTC

Tulu

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Sales $11.14B >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Net $1.78B >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q Adj EPS $1.26 >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17. juuli 2025, 11:30 UTC

Tulu

Abbott Labs 2Q EPS $1.01 >ABT

17. juuli 2025, 09:08 UTC

Kuumad aktsiad

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1. juuli 2025, 18:41 UTC

Omandamised, ülevõtmised, äriostud

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16. apr 2025, 15:09 UTC

Market Talk

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16. apr 2025, 14:17 UTC

Tulu

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16. apr 2025, 11:34 UTC

Tulu

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16. apr 2025, 11:33 UTC

Tulu

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16. apr 2025, 11:32 UTC

Tulu

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16. apr 2025, 11:32 UTC

Tulu

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16. apr 2025, 11:31 UTC

Tulu

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Reaffirms Full-Yr Guidance

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q Sales $10.36B >ABT

16. apr 2025, 11:30 UTC

Tulu

Abbott Labs 1Q Net $1.33B >ABT

Võrdlus sarnastega

Hinnamuutus

Abbott Laboratories Prognoos

Hinnasiht

By TipRanks

17.79% tõus

12 kuu keskmine prognoos

Keskmine 145.67 USD  17.79%

Kõrge 159 USD

Madal 135 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Abbott Laboratories 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

16

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

132.82 / 134.43Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

138 / 376 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.